Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

09.08.2022 - Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022 John ...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,John Evans ,Dan Budwick ,Astra Zeneca ,Chelcie Lister ,Beam Therapeutics Inc ,Federation Of American Societies For Experimental Biology ,Drug Administration ,American Society Of Cell ,Nasdaq ,Novartis ,Research Development Rd Expenses ,Exchange Commission ,Strategic Communications ,Development Committee At Celgene ,Mckinsey Company ,Bristol Myers Squibb ,Chief Commercial ,Second Quarter ,Cash Equivalents ,Marketable Securities ,Support Advancement ,Broad Precision Genetic Medicines ,American Society ,Gene Therapy ,Hepatitisb Virus ,American Societies ,Experimental Biology ,Genome Engineering Conference ,Engineered Stem Cell Antibody Paired ,Development Committee ,Verve Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Consolidated Balance Sheet Data ,Consolidated Statement ,Months Ended June ,